BioCentury | Aug 3, 2017
Tools & Techniques

Click bait

...probing strategy, GSK tapped the chemoproteomics expertise of its Cellzome GmbH unit, acquired in 2012. Cellzome...
...definitely among the smallest that have ever been used, unless you consider radioactivity." Paola Grandi, Cellzome...
...we're investing in further developing the method." Gitte Neubauer, Cellzome Gitte Neubauer, head of GSK's Cellzome...
BioCentury | Oct 6, 2014
Finance

Atlas' next chapter

...two exits were the asset-centric, build-to-buy migraine play Arteaus Therapeutics LLC , and proteomics company Cellzome AG...
...reacquired by Eli Lilly & Co. in January. And GlaxoSmithKline plc bought the 80% of Cellzome...
BioCentury | Apr 17, 2014
Cover Story

Contaminating cancer genomes

...SVP of biology at proteomics company Cellzome AG before joining CeMM in 2004. GlaxoSmithKline plc acquired Cellzome...
BioCentury | Oct 17, 2013
Strategy

Clinical takeoff for new epigenetic targets

...an exclusive option to acquire the company. Other notable deals include GlaxoSmithKline plc taking out Cellzome AG...
...program, plus double-digit royalties on ex-U.S. sales April 2012 Cellzome AG; GlaxoSmithKline (LSE:GSK; NYSE:GSK) GSK acquires Cellzome...
...partnered in 2010 to discover small molecules against epigenetic targets GSK acquires the 80.02% of Cellzome...
BioCentury | Jul 12, 2012
Targets & Mechanisms

More druggable than MYC

...Cold Spring Harbor Laboratory and Dana-Farber Cancer Institute and a team from GlaxoSmithKline plc , Cellzome AG...
...online July 12, 2012 Companies and Institutions Mentioned Baylor College of Medicine , Houston, Texas Cellzome AG...
BioCentury | Jul 2, 2012
Strategy

Revving the engine

...professor of cell biology at Harvard Medical School . Scientific co-founder of Exelixis Inc. (NASDAQ:EXEL); Cellzome AG...
BioCentury | May 24, 2012
Targets & Mechanisms

Getting selective for gamma

...phosphoinositide 3-kinase . 1,2 Exelixis plans to out-license its inhibitors, whereas last week's acquisition of Cellzome...
...inflammatory processes implicated in atherosclerosis and certain forms of metabolic disorders," said Rommel. Going native Cellzome...
...Gitte Neubauer, Cellzome AG, Heidelberg, Germany e-mail: gitte.neubauer@cellzome.com Contact: Marcus Bantscheff, same affiliation as above e-mail: marcus.bantscheff@cellzome.com...
BioCentury | May 21, 2012
Company News

Cellzome, GlaxoSmithKline deal

...Cellzome it does not already own for £61 million ($98 million) in cash. GSK said Cellzome's...
...Cellzome it does not already own for £61 million ($98 million) in cash. GSK said Cellzome's...
...2010 to use Cellzome's Episphere technology to discover small molecules against epigenetic targets. GSK and Cellzome...
BioCentury | May 21, 2012
Finance

Sale-zome

...Sale-zome VCs will barely make a return on their investment in German proteomics play Cellzome AG...
...partner GlaxoSmithKline plc (LSE:GSK; NYSE:GSK). GSK last week said it will acquire the 80% of Cellzome...
...it does not already own for £61 million ($98 million) in cash. Founded in 2000, Cellzome...
BioCentury | May 17, 2012
Distillery Therapeutics

Indication: Various

...Cellzome AG include using the in vitro screening platform to identify additional highly selective kinase inhibitors. Cellzome...
...Chem. Biol.; published online April 29, 2012; doi:10.1038/nchembio.957 Contact: Gitte Neubauer, Cellzome AG, Heidelberg, Germany e-mail: gitte.neubauer@cellzome.com BC...
Items per page:
1 - 10 of 99
BioCentury | Aug 3, 2017
Tools & Techniques

Click bait

...probing strategy, GSK tapped the chemoproteomics expertise of its Cellzome GmbH unit, acquired in 2012. Cellzome...
...definitely among the smallest that have ever been used, unless you consider radioactivity." Paola Grandi, Cellzome...
...we're investing in further developing the method." Gitte Neubauer, Cellzome Gitte Neubauer, head of GSK's Cellzome...
BioCentury | Oct 6, 2014
Finance

Atlas' next chapter

...two exits were the asset-centric, build-to-buy migraine play Arteaus Therapeutics LLC , and proteomics company Cellzome AG...
...reacquired by Eli Lilly & Co. in January. And GlaxoSmithKline plc bought the 80% of Cellzome...
BioCentury | Apr 17, 2014
Cover Story

Contaminating cancer genomes

...SVP of biology at proteomics company Cellzome AG before joining CeMM in 2004. GlaxoSmithKline plc acquired Cellzome...
BioCentury | Oct 17, 2013
Strategy

Clinical takeoff for new epigenetic targets

...an exclusive option to acquire the company. Other notable deals include GlaxoSmithKline plc taking out Cellzome AG...
...program, plus double-digit royalties on ex-U.S. sales April 2012 Cellzome AG; GlaxoSmithKline (LSE:GSK; NYSE:GSK) GSK acquires Cellzome...
...partnered in 2010 to discover small molecules against epigenetic targets GSK acquires the 80.02% of Cellzome...
BioCentury | Jul 12, 2012
Targets & Mechanisms

More druggable than MYC

...Cold Spring Harbor Laboratory and Dana-Farber Cancer Institute and a team from GlaxoSmithKline plc , Cellzome AG...
...online July 12, 2012 Companies and Institutions Mentioned Baylor College of Medicine , Houston, Texas Cellzome AG...
BioCentury | Jul 2, 2012
Strategy

Revving the engine

...professor of cell biology at Harvard Medical School . Scientific co-founder of Exelixis Inc. (NASDAQ:EXEL); Cellzome AG...
BioCentury | May 24, 2012
Targets & Mechanisms

Getting selective for gamma

...phosphoinositide 3-kinase . 1,2 Exelixis plans to out-license its inhibitors, whereas last week's acquisition of Cellzome...
...inflammatory processes implicated in atherosclerosis and certain forms of metabolic disorders," said Rommel. Going native Cellzome...
...Gitte Neubauer, Cellzome AG, Heidelberg, Germany e-mail: gitte.neubauer@cellzome.com Contact: Marcus Bantscheff, same affiliation as above e-mail: marcus.bantscheff@cellzome.com...
BioCentury | May 21, 2012
Company News

Cellzome, GlaxoSmithKline deal

...Cellzome it does not already own for £61 million ($98 million) in cash. GSK said Cellzome's...
...Cellzome it does not already own for £61 million ($98 million) in cash. GSK said Cellzome's...
...2010 to use Cellzome's Episphere technology to discover small molecules against epigenetic targets. GSK and Cellzome...
BioCentury | May 21, 2012
Finance

Sale-zome

...Sale-zome VCs will barely make a return on their investment in German proteomics play Cellzome AG...
...partner GlaxoSmithKline plc (LSE:GSK; NYSE:GSK). GSK last week said it will acquire the 80% of Cellzome...
...it does not already own for £61 million ($98 million) in cash. Founded in 2000, Cellzome...
BioCentury | May 17, 2012
Distillery Therapeutics

Indication: Various

...Cellzome AG include using the in vitro screening platform to identify additional highly selective kinase inhibitors. Cellzome...
...Chem. Biol.; published online April 29, 2012; doi:10.1038/nchembio.957 Contact: Gitte Neubauer, Cellzome AG, Heidelberg, Germany e-mail: gitte.neubauer@cellzome.com BC...
Items per page:
1 - 10 of 99